Active Older Adult Program on Health and Well-being

The Effects of an Active Older Adult Program at the Dan Abraham Healthy Living Center on Health and Well-being

The purpose of this study is to determine whether a structured 12-week program designed for older adults will improve physical function and, in parallel, circulating biomarkers of aging

Study Overview

• Status: Completed
• Conditions: Older Adult

• Study Type: Observational
• Enrollment (Actual): 33

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Mayo Clinic in Rochester

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

The target population consists of The Dan Abraham Healthy Living Center (DAHLC) members 60 years of age and older who plan to participate in the Active Older Adult Program.

Description

Inclusion Criteria:

• Men and women age 55 years or older.
• Membership at the DAHLC.
• New to AOA (Active Older Adult) Program and commitment to full participation in the twelve-week program.
• Must be able to get down and off the floor with little assistance.

Exclusion Criteria:

• Inability to provide informed consent.
• Previous participation in the AOA Program at the DAHLC.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in repeated chair rise time	Chair stand test where participants will perform a chair rise movement for five repetitions. The series of 5 repetitions will be timed and measured in seconds.	Baseline to end of study, approximately 14 weeks
Change in plasma protein levels reflective of biological age	Blood samples will be obtained at baseline and at 12 weeks. The concentration of target proteins (pg/mL) in the plasma will be measured and compared between baseline and week 12.	Baseline, week 12
Change in expression of senescence-related genes in blood cells	Blood samples will be obtained at baseline and at 12 weeks. The expression of senescence-related genes (arbitrary units) will be measured in immune cells isolated from whole blood and compared between baseline and week 12.	Baseline, week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Self-reported Physical Function	Measured using the Physical Component Scale (PCS) from the 12-Item short form general health survey (SF-12).	Baseline, week 12
Change in Performance-based Physical Function	Measured using the timed up-and-go test (seconds to complete).	Baseline, week 12
Change in Mental Function	Measured using the Mental Component Scale (MCS) from the 12-Item short form general health survey (SF-12)	Baseline, week 12
Change in self-assessment of well-being	Measured using a linear analogue self-assessment scale of well-being from 0 ("as bad as it can be") to 10 ("as good as it can be") of mental, physical, emotional, and spiritual well-being, level of social activity, and overall quality of life during the past week	Baseline, week 12

Collaborators and Investigators

• Sponsor: Mayo Clinic
• Investigators: Principal Investigator: Nathan LeBrasseur, PhD, MS, Mayo Clinic

Publications and helpful links

Helpful Links

• Mayo Clinic Clinical Trials

Study record dates

Study Major Dates

• Study Start (Actual): August 7, 2018
• Primary Completion (Actual): April 2, 2020
• Study Completion (Actual): April 2, 2020

Study Registration Dates

• First Submitted: May 17, 2021
• First Submitted That Met QC Criteria: May 19, 2021
• First Posted (Actual): May 21, 2021

Study Record Updates

• Last Update Posted (Actual): May 21, 2021
• Last Update Submitted That Met QC Criteria: May 19, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: 18-001769

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No